Freestone Grove Partners’s Astera Labs ALAB Stock Holding History

Freestone Grove Partners’s Portfolio ALAB Stock Details ALAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-84,296	Closed	-$7.62M	–	931
2025 Q2	$7.62M	Buy	+84,296	New	+$6.66M	0.06%	303

Other funds holding ALAB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Amundi Paris, France $367B AUM 31.23% 1-Year Est. Return

Freestone Grove Partners's ALAB Position: Q3 2025 in Review

Freestone Grove Partners sold out of Astera Labs (ALAB) in Q3 2025, closing a stake of 84,296 shares — an estimated $7.62M sold.

Freestone Grove Partners first reported a position in ALAB in Q2 2025 and held it in 1 quarter. The position peaked at $7.62M in Q2 2025. 657 funds tracked by Wall St. Rank hold ALAB as of Q3 2025.

Freestone Grove Partners reported no remaining Astera Labs position as of Q3 2025 after selling out during the quarter.
Freestone Grove Partners sold 84,296 Astera Labs shares in Q3 2025, an estimated $7.62M.
Freestone Grove Partners first reported a position in Astera Labs in Q2 2025 and held it in 1 quarter.
Freestone Grove Partners's Astera Labs position peaked at $7.62M in Q2 2025.
657 funds tracked by Wall St. Rank held Astera Labs as of Q3 2025.

Based on Freestone Grove Partners's 13F filing for Q3 2025, filed 14 Nov 2025.